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Abstract
Background: Imaging and histology of clear-cell ependymoma and cerebellum-based hemangioblastoma are
similar; distinguishing between them is a diagnostic challenge.
Case presentation: A 62-year-old Chinese woman presented with an intermittent headache of 8 years’ duration.
Computed tomography and magnetic resonance imaging revealed a mass in the cerebellum. Neurological imaging
suggested hemangioblastoma (HB). Histologically, the tumor included cellular and paucicellular areas, in which cells were
arranged in nests or diffusely distributed; and a highly vascular area, in which tumor cells were arranged in clusters and
separated by capillaries. At low magnification, the tumor mimicked cellular HB, but at high magnification, tumor cells
showed clear cytoplasm instead of the vacuolated cytoplasm typically observed in HB. Moreover, spindly, bipolar
elements resembling tanycytes were observed within the nest structures. Although these features indicated the possibility
of ependymoma, neither true ependymal rosettes nor an ependymal-lined profile was observed. The tumor was
characterized by prominent vascularity, but glomeruloid formation was absent. We saw pleomorphism in foci of some
tumor giant cells, but pathologic mitosis and palisaded necrosis were absent. Most tumor cells were positive for glial
fibrillary acidic protein and S100. Epithelial membrane antigen was expressed with a paranuclear dot-like or a ring-like
pattern. The Ki-67 index was approximately 2%. Considering the patient’s symptom, neurological imaging, and
pathological findings, she was diagnosed as cerebellar ependymoma (WHO grade II).
Conclusions: Here, we report a case of ependymoma with overlapping clear-cell and tanycytic features, and review the
literature to evaluate its real incidence. Pathologists should consider this rare diagnosis when confronted with a similar
presentation.
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Background
Ependymoma is a slow-growing tumor that accounts for
2–9% of all neuroepithelial tumors and 6–12% of all
intracranial tumors in children [1–3]. Ependymoma can
develop in all age groups with no sex predilection, but
its incidence is correlated with histological type and lo-
cation. Whereas infratentorial ependymomas are more
frequent in children, spinal ependymomas typically de-
velop in adults [1, 2]. Within the ventricular system and
spinal canal, the 4th ventricle and spinal cord are the
most common sites for this tumor, followed by the
lateral ventricles and the third ventricle [1]. Rare extra-
neural ependymomas have reportedly originated in the
ovaries, broad ligaments, peri-adnexal pelvic tissues, soft
tissues, mediastinum, lung, liver and the sacrococcygeal
area, although female genital tract and mediastinal cases
may well represent monodermal teratomas [1, 4]. Ac-
cording to 2016 World Health Organization (WHO)
Central Nervous System (CNS) classification, ependymo-
mas include three histopathological variants: papillary
ependymoma (PE), clear-cell ependymoma (CCE), and
tanycytic ependymoma (TE) [5]. Recently, one genetic-
ally defined ependymoma subtype has been added to the
2016 CNS WHO as a novel entity: Ependymoma, RELA
fusion-positive [5]. which accounts for most supratentor-
ial tumors in children [6, 7]. Occasionally, however,
ependymomas present with increased cellularity and mi-
totic activity, often associated with microvascular prolif-
eration and pseudo-palisading necrosis. These tumors
are designated as anaplastic ependymoma (WHO grade
III), which is associated with aggressive behavior and
unfavorable prognosis [1, 4]. Of the three variants, clear-
cell and tanycytic ependymomas are uncommon. In
contrast to the other variants of ependymomas, CCEs
are associated with aggressive behavior and early recur-
rence, even with gross total resection, and need more ac-
tive management [8, 9]. Here, we present a rare case of
cerebellar ependymoma with overlapping features of
clear-cell and tanycytic variants in an adult female,
which mimicked hemangioblastoma (HB) on histology,




A 62-year-old Chinese woman was admitted to our hos-
pital with a history of 8 years’ intermittent headache,
which had been aggravating over the previous week. Her
family history was irrelevant to the present illness. Gen-
eral and elemental neurological exams were normal.
Contrast-enhanced computed tomography (CT; 230 HU;
Fig. 1a, b) showed an oval mass (3.1 × 1.6 cm) with het-
erogeneous enhancement in the right cerebellum. Com-
puted tomographic angiography (CTA) showed a highly
vascular tumor; no obvious change was found on bilat-
eral basilar arteries, vertebral arteries or posterior cere-
bral arteries (Fig.1c, d). Neurological imaging suggested
HB. A suboccipital craniotomy of the posterior fossa was
performed for tumor resection. The mass was demar-
cated from the surrounding cerebellum tissue with focal
slight adhesion. A tumor 3.2 × 2 × 1.7 cm in size was
completely resected. The patient is alive with no sign of
tumor recurrence or metastasis after 9 months of
follow-up.
Materials and methods
The whole mass was completely sampled and fixed in
10% formalin, and then embedded in paraffin. A series
4-μm-thick sections was cut from each paraffin-
embedded block; the top and the bottom sections were
stained with hematoxylin/eosin to ensure the existence
of tumor tissue, and the others in the middle were used
for further IHC analyses. Commercially available predi-
luted monoclonal antibodies directed against epithelial
membrane antigen (EMA), glial fibrillary acidic protein
(GFAP), oligodendrocyte lineage transcription factor 2
(olig2), NeuN, synaptophysin, isocitrate dehydrogenase-1
(IDH1), CD56, S100, vimentin, CD34, p53, inhibin-α,
D2-40, and Ki-67 were purchased from Mai Xin Inc.,
Fuzhou, China. IHC staining was performed using the
streptavidin-peroxidase system (Ultrasensitive; Mai Xin
Inc., Fuzhou, China) according to the manufacturer’s in-
structions. The primary antibody was replaced with
phosphate-buffered saline as for negative controls.
Chromosome 1p and 19q co-deletion analysis
We performed fluorescent in situ hybridization (FISH) to
check for deletions of chromosomes 1p and 19q. Dual-
color-probe hybridization was performed with Vysis 1p36/
1q25 and 19q13/19p13 FISH Probe Kit (Abbott Molecular,
USA) according to manufacturer’s instructions. At least
100 non-overlapping nuclei were counted; samples were
considered to be 1p- or 19q-deleted when >30% of
counted nuclei presented one target (red) signal and two
reference (green) signals.
Microscopic features
Histologically, the tumor had a relative clear boundary
(Fig. 2a), and composed of highly vascular, cellular, and
paucicellular areas (Fig. 2b–e). In the highly vascular
area, the tumor was characterized by prominent vascu-
larity, with an abundant vascular meshwork, and clusters
of clear cells that mimicked reticular HB (Fig. 1b);
whereas tumor cells in the paucicellular (Fig. 2c) and
cellular areas (Fig. 2d) were arranged in nests or diffusely
distributed, which mimicked the cellular variant of HB.
The tumor cells were characterized by clear cytoplasm
(Fig. 2f–h), but the typical fat-laden vacuolated stromal
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Fig. 1 Imaging examination results. Contrast-enhanced CT reveals an oval mass with heterogeneous enhancement in the right cerebellum. (a: coronal
view; b: sagittal view). CTA showed tumor with abundant blood supply (c: coronal view; d: sagittal view)
Fig. 2 Histological features of the current case. a: The low magnification of the whole slide showed the tumor with a relatively clear boundary. b-e: The
tumor composed of highly vascular area, cellular area and paucicellular area. f-h: In all three regions, tumor cells with clear cytoplasm could be observed.
The arrows indicated the giant tumors. i: Foci of spindly and bipolar cells resemble tanycytes were observed within the tumor. j: Spindly, bipolar elements
may exist in the midst of the cellular nest surrounding by the clear cells. k: Nuclei of these cells in the midst exhibited the salt and pepper speckling. The
arrows indicated the giant tumors indicated the area of tanycytic variant. l: Foci of giant tumor cells with marked pleomorphism. The arrows indicated the
giant tumors
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cells in HB were absent. Spindly bipolar cells resembling
tanycytes were also observed within the tumor (Fig. 2i),
some of which were seen in the centers of nests surround-
ing by clear cells. This unique histological structure was
detected in ~ 50% of the tumor area (Fig. 2d, j, k). Nuclei
of these cells exhibited salt-and-pepper speckling with
elongated cytoplasmic processes (Fig. 2k). Although these
features suggested ependymoma, neither true ependymal
rosettes nor ependymal-lined profile were observed. No
calcification was found. The tumor was characterized by
the prominent vascularity, but glomeruloid formation was
absent. Despite the marked focal pleomorphism (Fig. 2l),
pseudo-palisading necrosis and atypical mitoses were not
present.
Immunohistochemistry
CD34 outlined the rich and delicate vascular channels
(Fig. 3a, b). Epithelial membrane antigen was expressed in
paranuclear dot-like or a ring-like patterns (Fig. 3c, d).
The tumor cells were diffusely positive for GFAP (Fig. 3e),
CD56 (Fig. 3f), S100 (Fig. 3g), and vimentin, but negative
for CD34 (Fig. 3b), synaptophysin (Fig. 3h), olig2 (Fig. 3i),
inhibin-α (Fig. 3j), NeuN (Fig. 3k), D2-40, P53 and IDH1.
The Ki-67 labeling index was approximately 2%, even in
the cellular area with prominent cell pleomorphism
(Fig. 3l).
Chromosome 1p and 19q co-deletion analysis
Neither 1p nor 19q deletion was detected in the current
case (Fig. 4a, b).
Discussion
According to the 2016 CNS WHO classification, ependy-
momas include three histopathological variants: PE, CCE,
and TE. Rare ependymoma variants include ependymoma
with lipomatous differentiation, giant-cell ependymoma,
ependymoma with extensive tumor cell vacuolation, mel-
anotic ependymoma, signet-ring cell ependymoma, ovar-
ian ependymoma, ependymoma with neuropil-like islands
(ENI), and ganglioglioma with a tanycytic glial component
Fig. 3 Immunohistochemical staining. a-b: CD34 underlined the rich and delicate vascular channels, while the tumor cells were negative for CD34. c-d:
The tumor cells expressed EMA in a paranuclear dot-like or a ring-like pattern. e-k: The tumor cells were diffusely positive for GFAP, CD56 and S100, but
negative for synaptophysin, olig2, inhibin-α and NeuN. l: The Ki-67 labeling index was approximately 2%
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[1]. To avoid misdiagnosis, comprehending the histological
features of each variant of ependymoma is important.
In the current case, the tumor was characterized by
the overlapping features of clear-cell and tanycytic vari-
ants of ependymoma. Because of the rarity of this histo-
logical feature, we reviewed literature for previously
reported cerebellar clear-cell [9–14] and intracranial
tanycytic [15–24] variant cases (Tables 1 and 2). How-
ever, the unique feature in this case—spindly bipolar
cells surrounded by clear cells, forming cellular nests—-
was never described in any of these English-language
studies. This novel histological pattern indicates that
these two subtypes of ependymoma may coexist in the
same tumor.
Because of our case’s histological similarity to CCE, we
first reviewed literature on this ependymoma variant.
CCE is a rare brain tumor, accounting for 0.3% of all gli-
omas [9]. To date (and to our knowledge), only 27 re-
ports in the English-language literature describe 69 cases
[8, 9, 12, 25–30]. CCE has a predilection for the
supratentorial region compared with classical ependy-
moma subtypes. Approximately 12 cases reportedly de-
veloped in the cerebellum (Table 1) [9–14]. Given the
similarities in neuroimaging and histology, differential
diagnosis between CCE and HB is clinically challenging.
Moreover, CCE often lacks ependymomatous features
such as ependymal rosettes, perivascular rosettes, or
ependymal canals, which makes diagnosis more compli-
cated. In a retrospective study, eight cases that were pre-
viously interpreted as hemangioblastomas were actually
CCEs [12]. In our case, the region with abundant capil-
lary meshwork resembled a reticular HB, whereas the
cellular area with clusters of clear cells could be inter-
preted as a cellular HB counterpart. The immunopheno-
type (S-100+/CD56+/NSE+) would also have supported
the diagnosis of HB, if the typical paranuclear dot-like or
a ring-like pattern of EMA expression had been missed
without carefully observation. Cellular HB may express
GFAP, but intensity is weaker and less extensive than in
ependymoma. Notably, the current case showed neither
Fig. 4 Chromosome 1p and 19q co-deletion analysis. Neither 1p (a) nor 19q (b) deletion was detected in the current case
Table 1 Summary of previously reported cerebellar clear-cell ependymoma in the literature
Author Year No. of cases Age/sex Follow-up (months) Outcome Recurrence
Kawano et al. [10] 1989 2 26/M 144 Dead Yes
55/F 48 NA NA
Kakita et al. [11] 1995 1 64/F NA NA NA
Kawano et al. [12] 1999 6 50/M 0 Dead NA
64/M 60 Dead NA
29/M 120 NA Yes
45/M 120 NA No
43/M 132 NA No
23/M 120 NA No
Hayashi et al. [13] 2005 1 67/M NA SD No
Kim et al. [14] 2007 1 3/F 10 NED No
Nagamatsu et al. [9] 2009 1 57/M 40 NA No
NA not available, NED no evidence of disease, SD stable disease
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the typical fat-laden vacuolation nor inhibin-α positivity
of HB. Vacuolated cytoplasm may be found in CCE, but
is usually limited to focal area. Therefore, the clear vacu-
olated cytoplasm was a diagnostic clue for the HB. The
IHC panel was also helpful for the definite diagnosis, es-
pecially as paranuclear dot-like and ring-like patterns for
EMA could be observed.
Compared with the other ependymomas (WHO grade
II), CCE usually present with aggressive behavior and bad
prognosis, with a recurrence rate of 60% [9, 31]. In
addition, this variant is always accompanied with high Ki-
67 index and p53 overexpression [32]. However, our pa-
tient is alive with no tumor recurrence or metastasis after
9 months of follow-up. Whether the tumor with overlap-
ping features of both CCE and TE has a relatively favor-
able biological behavior compared with the typical CCE
remains to be determined in the long-term follow-up.
We next reviewed the literature om TE. TEs are
typically encountered at spinal levels. Intracranial TE
is extremely rare; only 13 cases are currently reported
(Table 2) [15–24]. Primary cerebellar TE has not been
reported in English-language literature. TE usually
presents with a well-demarcated mass in neurological
imaging. The typical histological feature for TE is pre-
dominantly fascicular architecture with variable width
and cell density. Typified by elongated spindly bipolar
cells possessing thin eosinophilic fibrillary processes,
it has been speculated that this variant of ependy-
moma resembles the primitive radial glia-like tany-
cytes and therefore termed as TE. In contrast to the
classic ependymoma, ependymal rosettes are usually
absent or only ill-defined pseudorosettes formed in
TE, while the nuclei exhibit the typical feature of
salt-and-pepper speckling of other variants of ependy-
momas. Mitoses and necrosis are hardly observed in
TE. Occasionally, hyalined vessel walls and calco-
spherites may be observed which presents the degen-
erative changes.
Based on the focal nuclear pleomorphism, giant-cell
ependymoma, anaplastic ependymoma or giant-cell glio-
blastoma should be considered into the differential diag-
nosis. Although the nuclear pleomorphism was obvious
in focal area, neither significant mitotic activity nor
pseudo-palisading necrosis were seen in the present
case. In addition, the Ki-67 labeling index was low and
microvascular proliferation was absent in this case.
Therefore, only the nuclear pleomorphism is insufficient
to render a diagnosis of anaplastic ependymoma. Simi-
larly, the histological features also do not support the
diagnosis of giant-cell glioblastoma. In addition, giant
cells in current case were limited to focal areas and did
not constitute the major component for rendering a
diagnosis of giant-cell ependymoma.
In this case, the spindly bipolar cells that formed nests
amid clear cells prompted us to consider another variant
of ependymoma: ENI. The histological feature in current
case was similar to ENI, both of them formed numerous
islands composed of a fibrillary central core which was
surrounded by small, round to oval tumor cells. The key
point to distinguish between them was the histological
origin of the fibrillary central core. As termed as ENI, the
fibrillary central core was composed of neuropil-like
matrix and should be labeled by synaptophysin and NeuN.
Moreover, the small, round surrounding cells were actu-
ally neurocytic cells and therefore should also be labeled
by synaptophysin and NeuN. Only sporadic reports de-
scribed this seldom variant with unfavorable prognosis
[33]. Unlike ENI, specimen tumor cells in this case were
positive for GFAP and S100, but not synaptophysin and
NeuN, which did not support the diagnosis of ENI.
Table 2 Summary of previously reported intracranial tanycytic ependymoma in the literature
Author Year No. of cases Age/sex Location Follow-up (months) Outcome Recurrence
Friede et al. [24] 1978 4 3.5/M the fourth ventricle NA NA NA
10/M the fourth ventricle NA NA NA
34/M the fourth ventricle NA NA NA
75/F foramen of Monro NA NA NA
Daneyemez et al. [15] 1999 1 42/M right lateral ventricle 36 NED No
Hayashi et al. [16] 2000 1 51/M right frontal lobe 14 NED No
Richards et al. [17] 2004 1 17/M subcortical white matter of the left frontal lobe 13 NED No
Ragel et al. [18] 2005 1 55/F the third ventricle 3 SD No
Zhang et al. [19] 2008 1 38/M right lateral ventricle 8 SD No
Du et al. [23] 2009 1 36/Male Lateral ventricle NA NA NA
Arvanitis et al. [22] 2013 1 40/M lateral ventricle-anterior horn NA NA NA
Agarwal et al. [20] 2014 1 44/F the third ventricle 12 SD No
Kambe et al. [21] 2014 1 2/M right parietal lobe NA NA No
NA not available, NED no evidence of disease, SD stable disease
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Finally, oligodendroglioma should be included in the
different diagnosis because of the numerous clear tumor
cells. In the current case, the immunophenotype (nega-
tive for olig2, and EMA expressed in paranuclear dot-
like or a ring-like patterns), together with the negative
results for chromosome 1p and 19q deletion analysis,
ruled out the diagnosis of oligodendroglioma.
Conclusion
This description and review of features in this case report
of cerebellar ependymoma with overlapping clear-cell and
tanycytic features are intended to make pathologists aware
of this rare histological feature, and help to avoid misdiag-
nosing this CNS tumor (WHO grade II) as HB, which is a
biologically benign tumor.
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